\
&
Contact us
This was 1 week ago
LocationCopenhagen (DK)
These two conferences take place under the Danish presidency and aim to advance the EU's green transition, focusing on bioeconomy and transformative governance for food systems and biodiversity. They will offer a platform for stakeholders to engage in discussions on strategy implementation.
The first conference on 2 December will feature the launch of the new EU Bioeconomy Strategy, aimed at promoting bio-based innovation for sustainable growth. Key topics will include enhancing the bioeconomy through science and governance.
The second conference on 3 December will address transformative governance necessary for achieving climate and biodiversity goals while ensuring a just green transition in the agriculture and food system.
On the third day there is a matchmaking for organisations and companies willing to collaborate in a Horizon Europe project.
You need to register for each event seperately but you can do it all on this website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.